Search Results

Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents

Globally operating CDMO committed to strengthening Germany as a research and production location Association grants Vetter extraordinary membership vfa recognizes the importance of pharmaceutical service providers in drug development and production Vetter serves on key vfa committees RAVENSBURG, Germany--( BUSINESS WIRE )-- Vetter, a leading globally operating contract development and manufacturing organization (CDMO), has joined the German Association o

Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, announced the acquisition of Spiegelberg GmbH & Co. KG, an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.

CDMO presents third sustainability report Voluntary reporting of sustainability targets and progress strengthens customer relationships through transparency and accountability Economic success and ambitious sustainability goals can be achieved in conjunction with one another Aiming to be completely climate-neutral by 2050, Vetter joins the Science Based Targets Initiative (SBTi) RAVENSBURG, Germany--( BUSINESS WIRE )-- Alongside its dynamic growth, Vette

An increase in project orders drives further site growth

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.